Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Industry Pushes A Broadened Meaning For “Orphan”

Executive Summary

BOSTON – Along with the surge in interest in drugs to treat rare or orphan diseases, there has been an increasingly strategic view of what qualifies as an orphan market, with companies looking to subdivide conditions to capitalize on the perceived advantages afforded by rare diseases, according to participants at the recent BioPharm America conference.

You may also be interested in...



Will March 2012 Mark The End Of Regulatory Limbo For Discovery’s Surfaxin?

Discovery Laboratories now believes March 2012 could mark the end of an almost eight-year regulatory odyssey to secure FDA approval of its synthetic surfactant Surfaxin (lucinactant).

Will March 2012 Mark The End Of Regulatory Limbo For Discovery’s Surfaxin?

Discovery Laboratories now believes March 2012 could mark the end of an almost eight-year regulatory odyssey to secure FDA approval of its synthetic surfactant Surfaxin (lucinactant).

Will March 2012 Mark The End Of Regulatory Limbo For Discovery's Surfaxin?

FDA has set a March 6 user fee date for action on Discovery Laboratories' synthetic surfactant, which was filed with the agency in 2004 but is now in its fifth review cycle.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel